Anne H Dantzig

7038077, May 2, 2006

Jan 9, 2002

10/465972

Anne Hollins Dantzig - Crawfordsville IN, US
James Allen Monn - Indianapolis IN, US
Stephanie Ann Sweetana - Carmel IN, US
Ana Belen Bueno Melendo - Madrid, ES
Alfonso De Dios - Madrid, ES
Carmen Dominguez-Fernandez - Madrid, ES
Marc Francis Herin - Perwez, BE
Luisa Maria Martin-Cabrejas - Madrid, ES
Jose Alfredo Martin - Madrid, ES
Maria Angeles Martinez-Grau - Madrid, ES
Carlos Montero Salgado - Madrid, ES
Concepcion Pedregal-Tercero - Madrid, ES

Eli Lilly and Company - Indianapolis IN

C07C 61/12

562501, 562502

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

52780643, Jan 11, 1994

May 4, 1992

7/878254

Dennis R. Berry - Greenwood IN
Anne H. Dantzig - Crawfordsville IN
Manuel Debono - Indianapolis IN
Robert Hamill - Greenwood IN
R. Michael Molloy - Danville IN
Raymond C. Yao - Carmel IN

Eli Lilly and Company - Indianapolis IN

A61K 3500
C12R 101
C12P 104

4352521

Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C. sub. 1-6 -alkyl ether and C. sub. 1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A. sub. 2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A. sub. 2 inhibitors that are also useful as antiinflammatory agents.

6270978, Aug 7, 2001

Jan 31, 1997

8/792485

Stuart W. Bright - Indianapolis IN
Anne H. Dantzig - Crawfordsville IN
Linda B. Tabas - Carmel IN
J. Richard Sportsman - Palo Alto CA

Eli lilly and Company - Indianapolis IN

G01N 3353
C07K 1400
C07K 1600

435 71

Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism.

55003460, Mar 19, 1996

Jun 29, 1993

8/084686

Stuart W. Bright - Indianapolis IN
Anne H. Dantzig - Crawfordsville IN
Linda B. Tabas - Carmel IN
J. Richard Sportsman - Palo Alto CA

Eli Lilly and Company - Indianapolis IN

G01N 33567
G01N 3353

435 721

Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.

57100187, Jan 20, 1998

Jun 5, 1995

8/463345

Anne H. Dantzig - Crawfordsville IN
Jo Ann Hoskins - Indianapolis IN
Paul L. Skatrud - Greenwood IN

Eli Lilly and Company - Indianapolis IN

C12D 2106

435 691

The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.

61243116, Sep 26, 2000

Jun 28, 1996

8/674771

Srinivasan Chandrasekhar - Indianapolis IN
Anne H. Dantzig - Crawfordsville IN
Robert L. Shepard - Noblesville IN
James J. Starling - Carmel IN
Mark A. Winter - Indianapolis IN

Eli Lilly and Company - Indianapolis IN

A61K 3144
A61K 3170
A61K 31535
A61K 31445
A61K 3140
A61K 31335
A61K 3116

514283

The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

58245103, Oct 20, 1998

Dec 1, 1994

8/347760

Stuart W. Bright - Indianapolis IN
Anne H. Dantzig - Crawfordsville IN
Linda B. Tabas - Carmel IN
J. Richard Sportsman - Palo Alto CA

Eli Lilly and Company - Indianapolis IN

C07K 1600
C12P 1208

435 7021

Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.

56208553, Apr 15, 1997

May 1, 1995

8/431560

Anne H. Dantzig - Crawfordsville IN
Jo A. Hoskins - Indianapolis IN
Paul L. Skatrud - Greenwood IN

Eli Lilly and Company - Indianapolis IN

G01N 33567

435 6

The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.